Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Chifumi Nagano"'
Autor:
Masanori Nozako, Takashi Koyama, Chifumi Nagano, Makoto Sato, Satoshi Matsumoto, Kiminobu Mitani, Reiko Yasufuku, Masayuki Kohashi, Tomohiro Yoshikawa
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143979 (2015)
Diabetic nephropathy develops in association with hyperglycemia, is aggravated by atherogenic factors such as dyslipidemia, and is sometimes initiated before obvious hyperglycemia is seen. However, the precise mechanisms of progression are still uncl
Externí odkaz:
https://doaj.org/article/a647ff492fe847a6a921f4f8c871856e
Autor:
Yuka Keyamura, Chifumi Nagano, Masayuki Kohashi, Manabu Niimi, Masanori Nozako, Takashi Koyama, Reiko Yasufuku, Ayako Imaizumi, Hiroyuki Itabe, Tomohiro Yoshikawa
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e96929 (2014)
OBJECTIVE: Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40
Externí odkaz:
https://doaj.org/article/2c7c9407e003408a97df6a6ab34be29f
Autor:
Hideki Ito, Kenji Uehara, Yutaka Matsumoto, Ayako Hashimoto, Chifumi Nagano, Manabu Niimi, Goro Miyakoda, Keisuke Nagano
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39374 (2012)
Cilostazol is clinically used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction and for the secondary prevention of brain infarction. Recently, it has been reported that cilostazol has preventive effects
Externí odkaz:
https://doaj.org/article/300c19786a9747c8885aa7b7d4cabaae
Autor:
Chifumi Nagano, Kaori Abe
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 105:106737
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00f2df6a3676161598c5aa3d6a0a6e6f
https://doi.org/10.1016/j.vascn.2020.106737
https://doi.org/10.1016/j.vascn.2020.106737
Autor:
Hiroyuki Itabe, Manabu Niimi, Masayuki Kohashi, Yuka Keyamura, Chifumi Nagano, Takashi Koyama, Masanori Nozako, Tomohiro Yoshikawa
Publikováno v:
Biological & Pharmaceutical Bulletin. 38:785-788
Atherosclerotic lesion formation starts during fetal development and progresses with age after adolescence. However, atherogenesis during the juvenile period has not been studied thoroughly. In this study, we examined the atherogenic susceptibility o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd21693444e5f4f364ed954bfca058cc
https://doi.org/10.1248/bpb.b14-00775
https://doi.org/10.1248/bpb.b14-00775
Autor:
Kiyoshi Takasuna, Natsumi Kato, Mahoko Asayama, Hideaki Mitsui, Chifumi Nagano, Sunao Hisada, Yayoi Honda
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10d9f0b2ca7017a861218d603a18f367
https://doi.org/10.1016/j.vascn.2019.05.163
https://doi.org/10.1016/j.vascn.2019.05.163
Publikováno v:
InflammoPharmacology. 10:391-399
Previous studies have suggested that rebamipide, a gastroprotective drug, might be effective for the treatment of aphthous oral ulcers in Behcet's disease patients. The aim of this study was to confirm the effect of rebamipide on experimentally induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abc74fda5cea2a443891f31155bf85a6
https://doi.org/10.1163/156856002321544864
https://doi.org/10.1163/156856002321544864
Autor:
Ayako Imaizumi, Manabu Niimi, Masanori Nozako, Hiroyuki Itabe, Chifumi Nagano, Tomohiro Yoshikawa, Yuka Keyamura, Takashi Koyama, Masayuki Kohashi, Reiko Yasufuku
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 5, p e96929 (2014)
PLoS ONE, Vol 9, Iss 5, p e96929 (2014)
OBJECTIVE: Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ec2d2172532844d8953b2625e61ce40
https://pubmed.ncbi.nlm.nih.gov/24810608
https://pubmed.ncbi.nlm.nih.gov/24810608
Autor:
Takashi Koyama, Makoto Sato, Satoshi Matsumoto, Masanori Nozako, Kiminobu Mitani, Reiko Yasufuku, Masayuki Kohashi, Tomohiro Yoshikawa, Chifumi Nagano
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143979 (2015)
PLoS ONE
PLoS ONE
Diabetic nephropathy develops in association with hyperglycemia, is aggravated by atherogenic factors such as dyslipidemia, and is sometimes initiated before obvious hyperglycemia is seen. However, the precise mechanisms of progression are still uncl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6568a766bfacf6ddd16dd659267ffb16
https://doi.org/10.1371/journal.pone.0143979
https://doi.org/10.1371/journal.pone.0143979
Autor:
Ayako Hashimoto, Goro Miyakoda, Yutaka Matsumoto, Keisuke Nagano, Kenji Uehara, Manabu Niimi, Chifumi Nagano, Hideki Ito
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39374 (2012)
PLoS ONE
PLoS ONE
Cilostazol is clinically used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction and for the secondary prevention of brain infarction. Recently, it has been reported that cilostazol has preventive effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceeb8d182f80418ca8e5881c7804d84f
https://doi.org/10.1371/journal.pone.0039374
https://doi.org/10.1371/journal.pone.0039374